Jan 10, 2024
Six of eight patients with nonactive secondary progressive multiple sclerosis (SPMS) being treated with foralumab nasal spray — all part of an intermediate-size expanded access program (EAP) allowing the therapy’s use — have experienced reductions in their fatigue...
Jan 10, 2024
Monte Rosa Therapeutics is planning to initiate a Phase 1 clinical trial to test MRT-6160, its investigational therapy for multiple sclerosis (MS) and other autoimmune diseases, by mid-2024. The trial will follow the submission of an an investigational new drug (IND)...
Jan 9, 2024
Let’s be honest, it’s very easy to admit that we love our significant others, but we may not always like them. That is naturally going to happen when you literally spend the rest of your life with someone. When the person you love has MS, things may not always make...
Jan 7, 2024
One way to engage your elected and public officials while also raising public awareness of Multiple Sclerosis is to obtain a ‘March is MS Awareness Month’ proclamation from your city or state. Proclamations are formal declarations issued by a person of...
Jan 5, 2024
An analysis of data covering nearly 200 people with multiple sclerosis (MS) found no association between dairy or gluten consumption and MS disease activity. While some specific diets for MS tend to restrict gluten and/or dairy, this study found that people who ate...
Dec 23, 2023
Tiziana Life Sciences has dosed the first patient in a Phase 2a clinical trial testing its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS). The trial will include about 54 participants, enrolled across six clinical sites....
